Skip to main content

Reditus Space

Reditus Space provides sustainable and scalable microgravity access as a service, facilitating in-space manufacturing for advanced materials and drug formulation. The company offers end-to-end services covering launch integration, autonomous in-orbit operations, and controlled reentry for payload recovery. This integrated approach unlocks commercial potential in Low Earth Orbit through reliable access and rapid mission turnaround.

Traction 10/10
Atlanta, United States · HQ
Founded 20233300+ followers
  • Aerospace
  • Manufacturing / Industry 4.0
  • New Materials
Updated yesterday

Funding

Raised to date

$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Will Sherman

CTO/Co-founder

Product

Problem

Manufacturing on Earth is constrained by gravity, which introduces defects and limits the purity and uniformity of materials, especially in semiconductors and pharmaceuticals. This impacts the performance and capabilities of advanced technologies and biomedical innovations.

Solution

Reditus Space offers microgravity manufacturing services in Low Earth Orbit (LEO) using fully reusable infrastructure. By eliminating the effects of gravity at the molecular level, Reditus Space enables the production of materials with unparalleled purity and uniformity. This results in enhanced performance and reduced defects in semiconductors, improved protein crystallization and drug formulation in pharmaceuticals, and overall superior material properties compared to Earth-based manufacturing.

Target Audience

Reditus Space targets semiconductor manufacturers, pharmaceutical companies, and research institutions seeking to leverage the benefits of microgravity for advanced material production and biomedical innovations.

Features

  • Microgravity environment for manufacturing processes.
  • Fully reusable space-based infrastructure.
  • Enhanced protein crystallization for pharmaceutical development.
  • Superior drug formulation capabilities.
  • Production of high-purity, uniform semiconductors.
  • Improved material properties at the molecular level.
This profile is AI-generated and may contain inaccuracies.